{"id":"acetyldigitoxin","rwe":[],"tags":[{"label":"acetyldigitoxin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium/potassium-transporting ATPase","category":"target"},{"label":"ATP1A1","category":"gene"},{"label":"ATP1A2","category":"gene"},{"label":"ATP1A3","category":"gene"},{"label":"C01AA01","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Atrial fibrillation","category":"indication"},{"label":"Congestive heart failure","category":"indication"},{"label":"Novartis","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Arrhythmia Agents","category":"pharmacology"},{"label":"Cardiotonic Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Novartis","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ACETYLDIGITOXIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:47:18.867522+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Acetyldigitoxin","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:47:25.694514+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:47:24.481260+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACETYLDIGITOXIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:47:24.658960+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sodium/potassium-transporting ATPase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:47:25.694423+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545057/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:47:25.359077+00:00"}},"allNames":"acylanid","offLabel":[],"synonyms":["acetyldigitoxin","acylanid","Desglucolanatoside A","alpha-Acetyldigitoxin"],"timeline":[{"date":"1975-04-24","type":"positive","source":"DrugCentral","milestone":"FDA approval (Novartis)"}],"aiSummary":"Acetyldigitoxin, also known as Acylanid, is a small molecule drug developed by Novartis that targets the sodium/potassium-transporting ATPase. It is used to treat atrial fibrillation and congestive heart failure. The drug is off-patent, meaning it is no longer protected by patents, and there are no generic manufacturers. Acetyldigitoxin was approved by the FDA in 1975 and has a bioavailability of 70%. As an off-patent drug, its commercial status is uncertain.","brandName":"Acylanid","ecosystem":[{"indication":"Atrial fibrillation","otherDrugs":[{"name":"bisoprolol","slug":"bisoprolol","company":"Teva Womens"},{"name":"clopidogrel","slug":"clopidogrel","company":"Sanofi Aventis Us"},{"name":"digoxin","slug":"digoxin","company":"Eurohlth Intl Sarl"},{"name":"diltiazem","slug":"diltiazem","company":"Valeant Intl"}],"globalPrevalence":59000000},{"indication":"Congestive heart failure","otherDrugs":[{"name":"enalapril","slug":"enalapril","company":"Valeant Pharms North"},{"name":"enalaprilat","slug":"enalaprilat","company":"Biovail Labs Intl"},{"name":"ubidecarenone","slug":"ubidecarenone","company":""}],"globalPrevalence":64000000}],"mechanism":{"target":"Sodium/potassium-transporting ATPase","novelty":"First-in-class","targets":[{"gene":"ATP1A1","source":"DrugCentral","target":"Sodium/potassium-transporting ATPase","protein":"Sodium/potassium-transporting ATPase subunit alpha-1"},{"gene":"ATP1A2","source":"DrugCentral","target":"Sodium/potassium-transporting ATPase","protein":"Sodium/potassium-transporting ATPase subunit alpha-2"},{"gene":"ATP1A3","source":"DrugCentral","target":"Sodium/potassium-transporting ATPase","protein":"Sodium/potassium-transporting ATPase subunit alpha-3"},{"gene":"ATP1A4","source":"DrugCentral","target":"Sodium/potassium-transporting ATPase","protein":"Sodium/potassium-transporting ATPase subunit alpha-4"},{"gene":"ATP1B1","source":"DrugCentral","target":"Sodium/potassium-transporting ATPase","protein":"Sodium/potassium-transporting ATPase subunit beta-1"},{"gene":"ATP1B2","source":"DrugCentral","target":"Sodium/potassium-transporting ATPase","protein":"Sodium/potassium-transporting ATPase subunit beta-2"},{"gene":"ATP1B3","source":"DrugCentral","target":"Sodium/potassium-transporting ATPase","protein":"Sodium/potassium-transporting ATPase subunit beta-3"},{"gene":"FXYD2","source":"DrugCentral","target":"Sodium/potassium-transporting ATPase","protein":"Sodium/potassium-transporting ATPase subunit gamma"}],"modality":"Small Molecule","drugClass":"acetyldigitoxin","explanation":"","oneSentence":"","technicalDetail":"Acetyldigitoxin acts as a cardiac glycoside that inhibits the sodium/potassium-transporting ATPase, leading to an increase in intracellular sodium and a decrease in intracellular potassium, which in turn increases the contractility of the heart muscle and slows the heart rate."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Acetyldigitoxin","title":"Acetyldigitoxin","extract":"Acetyldigitoxin is a cardiac glycoside. It is an acetyl derivative of digitoxin, found in the leaves of Digitalis species. It is used to treat cardiac failure, particularly that associated with tachycardia."},"commercial":{"launchDate":"1975","_launchSource":"DrugCentral (FDA 1975-04-24, NOVARTIS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/67","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACETYLDIGITOXIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Acetyldigitoxin","fields":["history","overview"],"source":"Wikipedia"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:23:53.858874","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:47:26.892367+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"digitoxin","drugSlug":"digitoxin","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"digoxin","drugSlug":"digoxin","fdaApproval":"1975-10-24","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"deslanoside","drugSlug":"deslanoside","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"acetyldigitoxin","indications":{"approved":[{"name":"Atrial fibrillation","source":"DrugCentral","snomedId":49436004,"regulator":"FDA","usPrevalence":6100000,"globalPrevalence":59000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet, 2023"},{"name":"Congestive heart failure","source":"DrugCentral","snomedId":42343007,"regulator":"FDA","usPrevalence":6200000,"globalPrevalence":64000000,"prevalenceMethod":"curated","prevalenceSource":"ESC Heart Failure, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"digitoxin","brandName":"digitoxin","genericName":"digitoxin","approvalYear":"","relationship":"same-class"},{"drugId":"digoxin","brandName":"digoxin","genericName":"digoxin","approvalYear":"1975","relationship":"same-class"},{"drugId":"deslanoside","brandName":"deslanoside","genericName":"deslanoside","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NDDF":"000596","UNII":"0ZV4Q4L2FU","CHEBI":"CHEBI:53773","INN_ID":"792","RXNORM":"132871","UMLSCUI":"C0520442","chemblId":"CHEMBL3545057","ChEMBL_ID":"CHEMBL3545057","KEGG_DRUG":"D06881","DRUGBANK_ID":"DB00511","PUBCHEM_CID":"5284512","SNOMEDCT_US":"7834009","IUPHAR_LIGAND_ID":"6794","MESH_DESCRIPTOR_UI":"D000112"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1975-","companyName":"Novartis","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"70%"},"publicationCount":113,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C01AA01","allCodes":["C01AA01"]},"biosimilarFilings":[],"originalDeveloper":"Novartis","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"1975","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:47:26.892367+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}